Avita Laboratories Profile
Key Indicators
- Authorised Capital ₹ 0.30 M
as on 08-12-2024
- Paid Up Capital ₹ 0.10 M
as on 08-12-2024
- Company Age 17 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Revenue -30.75%
(FY 2021)
- Profit -167.90%
(FY 2021)
- Ebitda -76.83%
(FY 2021)
- Net Worth -26.12%
(FY 2021)
- Total Assets 27.85%
(FY 2021)
About Avita Laboratories
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.30 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Amrendra Singh and Archana Singh serve as directors at the Company.
- CIN/LLPIN
U51397BR2007PTC013099
- Company No.
013099
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Jul 2007
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Patna
Industry
Company Details
- Location
Patna, Bihar, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Avita Laboratories Private Limited offer?
Avita Laboratories Private Limited offers a wide range of products and services, including Amoxicillin drugs, Amoxicillin Potassium Clavulanate Tablet, Antibiotic Tablets & Capsules, Cefixime Tablet, Antipyretic Medication, Paracetamol Tablets, Antacid Drugs, Allopathic Liver Tonic, Homeopathic Drugs, Homoeopathic Drops.
Who are the key members and board of directors at Avita Laboratories?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Amrendra Singh  | Director | 08-Apr-2023 | Current |
| Archana Singh | Director | 08-Apr-2023 | Current |
Financial Performance of Avita Laboratories.
Avita Laboratories Private Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 30.75% decrease. The company also saw a substantial fall in profitability, with a 167.9% decrease in profit. The company's net worth observed a substantial decline by a decrease of 26.12%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Avita Laboratories?
In 2021, Avita Laboratories had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Avita Laboratories?
Avita Laboratories has a workforce of 13 employees as of Apr 03, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Avita Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Avita Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
